Colchicine-The Divine Medicine against COVID-19.

ingentiumby ingentium

In Discovery Literature.

Publication date: Jul 16, 2024

Colchicine has a number of effects that suggest it may be useful in the treatment of COVID-19. Myeloid cells are a major source of dysregulated inflammation in COVID-19. The hyperactivation of the NLRP3 inflammasome and the subsequent cytokine storm take place precisely inside them and can lead to multiorgan damage and death. NLRP3 inflammasome inhibition has been assessed at micromolar colchicine concentrations which cannot be achieved in serum. However, colchicine has remarkable ability to accumulate intensively in leukocytes, where the cytokine storm is generated. Over 50 observational studies and randomized clinical trials, small randomized non-controlled trials, and retrospective cohort studies were initiated to test its healing effect in vivo, leading to conflicting, rather disappointing results. The WHO gives a “Strong recommendation against” the use of colchicine for COVID-19 treatment. This is because low doses of colchicine are always used, where the concentrations required to inhibit the NLRP3 inflammasome in leukocytes cannot be reached. Considering this, from March 2020, we started the administration of higher doses of colchicine. Our assumption was that a safe increase in colchicine doses to reach micromolar concentrations in leukocytes will result in NLRP3 inflammasome/cytokine storm inhibition. We demonstrated that in 785 inpatients treated with increasing doses of colchicine, mortality fell between two and seven times. Our data, including a large number of COVID-19 outpatients, showed that nearly 100% of the patients treated with this therapeutic regimen escaped hospitalization. In addition, post-COVID-19 symptoms in those treated with colchicine were significantly rarer. As a large number of viruses can overactivate the NLRP3 inflammasome (like seasonal influenza), we are convinced that higher colchicine doses would be useful in these cases as well.

Open Access PDF

Concepts Keywords
Myeloid colchicine doses
Outpatients colchicine toxicity
Serum COVID-19
Viruses cytokine storm
NLRP3 inflammasome

Semantics

Type Source Name
drug DRUGBANK Colchicine
disease MESH COVID-19
disease MESH inflammation
pathway REACTOME The NLRP3 inflammasome
disease MESH cytokine storm
disease MESH death
disease VO Viruses
disease VO Optaflu
disease MESH influenza
drug DRUGBANK Nitrogen
disease MESH joint pain
disease MESH gout
drug DRUGBANK Coenzyme M
disease VO USA
disease MESH familial Mediterranean fever
disease MESH rheumatic diseases
drug DRUGBANK Calcium
drug DRUGBANK N-Cyclohexyl-N’-phenyl-1 4-phenylenediamine
disease MESH osteoarthritis
disease MESH dermatoses
disease MESH aphthous stomatitis
disease MESH Sweet’s syndrome
disease MESH epidermolysis bullosa acquisita
disease MESH vasculitis
disease MESH erythema
disease MESH pyoderma gangrenosum
disease MESH acne
disease MESH calcinosis cutis
disease MESH keloids
disease MESH fibromatosis
disease MESH actinic keratosis
disease MESH relapsing polychondritis
disease MESH subcorneal pustular dermatosis
disease MESH erythema nodosum
disease MESH chronic urticaria
disease MESH syndrome
disease MESH pharyngitis
disease MESH adenitis
disease MESH leukocytoclastic vasculitis
disease VO leukocyte
disease MESH pericarditis
disease MESH atrial fibrillation
disease MESH stroke
disease MESH infarction
disease MESH acute coronary syndrome
disease MESH coronary artery disease
disease MESH ischemic stroke
disease MESH transient ischemic attack
disease MESH intracranial atherosclerosis
disease MESH arteriolosclerosis
disease VO dose
disease MESH cardiovascular diseases
pathway KEGG Apoptosis
disease MESH gastric cancer
pathway KEGG Gastric cancer
disease MESH hepatocellular carcinoma
pathway KEGG Hepatocellular carcinoma
disease MESH cholangiocarcinoma
disease MESH osteosarcoma
drug DRUGBANK Activated charcoal
disease IDO blood
disease VO Rho
drug DRUGBANK Nitric Oxide
disease MESH hepatitis
disease VO Respiratory syncytial virus
disease IDO production
drug DRUGBANK Cyclic Adenosine Monophosphate
drug DRUGBANK Oxygen
drug DRUGBANK Nitrite
disease IDO process
disease MESH ST elevation myocardial infarction
disease VO time
disease VO Glycoprotein
disease MESH drug interactions
disease IDO history
disease MESH chronic kidney disease
drug DRUGBANK Ethanol
drug DRUGBANK Atorvastatin
drug DRUGBANK Ibuprofen
drug DRUGBANK Diclofenac
drug DRUGBANK Furosemide
disease MESH suicide
disease MESH high blood pressure
disease MESH G6PD deficiency
disease MESH hypothyroidism
drug DRUGBANK Indometacin
drug DRUGBANK Zopiclone
drug DRUGBANK Topiramate
drug DRUGBANK Valproic Acid
drug DRUGBANK Olanzapine
drug DRUGBANK Lorazepam
drug DRUGBANK Levothyroxine
drug DRUGBANK Oxycodone
drug DRUGBANK Omeprazole
disease MESH pneumonia
disease MESH acute respiratory distress syndrome
disease MESH complications
disease MESH diabetes mellitus
disease MESH pericardial effusion
disease VO effective
disease VO organization
disease MESH allergic reactions
disease MESH anaphylaxis
disease MESH drug induced liver injury
disease MESH acute liver failure
disease VO intravenous route
drug DRUGBANK Ritonavir
drug DRUGBANK Ribostamycin
disease VO vaccinated
disease VO population
disease VO unvaccinated
drug DRUGBANK Spinosad
disease MESH long COVID
pathway KEGG Viral replication
disease VO ReCOV
drug DRUGBANK Tocilizumab
disease IDO cell
disease VO dead
drug DRUGBANK Efavirenz
drug DRUGBANK Diethylstilbestrol
disease MESH Calcium Pyrophosphate Deposition Disease
drug DRUGBANK Bismuth subgallate
disease MESH Ischemia
disease MESH myocardial infarction
drug DRUGBANK Bromhexine
drug DRUGBANK Hymecromone
drug DRUGBANK Baricitinib
disease MESH Arthritis
drug DRUGBANK N-acetylsulfanilyl chloride
disease MESH musculoskeletal diseases
disease MESH gouty arthritis
drug DRUGBANK Uric Acid
disease MESH lung injury
disease VO report
disease MESH Multiple organ failure
disease MESH hypertriglyceridemia
disease MESH Acute Renal Failure
disease MESH cardiogenic shock
drug DRUGBANK Loxoprofen
disease VO volume
disease MESH Emergency
drug DRUGBANK Silver
disease VO effectiveness
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH viral infection

Original Article

(Visited 2 times, 1 visits today)